|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000181104 |
Summary for F2R |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000181104 | Gene symbol | F2R |
| Gene name | coagulation factor II thrombin receptor | |
| HGNC | 3537 | |
| Entrez ID | 2149 | |
| Gene type | protein_coding | |
| Synonyms | F2R|TR|CF2R|PAR1|PAR-1 | |
| UniProtAcc | P25116 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000181104 | F2R | DB00086 | Streptokinase | BiotechDrug |
| ENSG00000181104 | F2R | DB05361 | SR-123781A | SmallMoleculeDrug |
| ENSG00000181104 | F2R | DB09030 | Vorapaxar | SmallMoleculeDrug |
| ENSG00000181104 | F2R | DB11300 | Thrombin | BiotechDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for F2R |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| F2R | 4.71e+03 | 1.27e+00 | 3.71e-01 | 3.42e+00 | 6.21e-04 | 4.36e-03 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| F2R | 1.42e+03 | 1.08e+00 | 3.96e-01 | 2.73e+00 | 6.36e-03 | 3.36e-02 | BLCA |
| F2R | 1.93e+03 | -1.23e+00 | 2.54e-01 | -4.85e+00 | 1.25e-06 | 4.63e-06 | KICH |
| F2R | 1.27e+03 | 1.07e+00 | 1.77e-01 | 6.04e+00 | 1.52e-09 | 7.76e-09 | COAD |
| F2R | 1.44e+03 | 1.01e+00 | 3.43e-01 | 2.94e+00 | 3.26e-03 | 9.58e-03 | READ |
Top |
Sex-biased somatic mutation for F2R |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for F2R |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25585647 | chr5:76716097 | CGI:chr5:76715295-76716467 | UTR,promoter,exon,gene body | 2.94e-02 | 1.66e-01 | -2.32e+00 | 2.04e-02 | 3.52e-02 | -1.37e-01 |
| BRCA | cg03043127 | chr5:76714833 | CGI:chr5:76715295-76716467 | promoter | 6.20e-01 | 7.90e-01 | -2.72e+00 | 6.46e-03 | 2.26e-02 | -1.70e-01 |
| STAD | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 7.53e-01 | 6.33e-01 | 7.15e+00 | 8.68e-13 | 7.29e-12 | 1.20e-01 |
| KIRP | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 1.81e-01 | 3.14e-01 | 2.69e+00 | 7.20e-03 | 1.73e-02 | -1.33e-01 |
| SARC | cg03043127 | chr5:76714833 | CGI:chr5:76715295-76716467 | promoter | 5.82e-01 | 4.66e-01 | 3.53e+00 | 4.09e-04 | 1.70e-03 | 1.16e-01 |
| PCPG | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 2.00e-01 | 3.33e-01 | 5.43e+00 | 5.61e-08 | 2.81e-07 | -1.33e-01 |
| PAAD | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 2.81e-01 | 4.37e-01 | 7.38e+00 | 1.61e-13 | 1.61e-12 | -1.56e-01 |
| READ | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 4.61e-01 | 6.18e-01 | 5.04e+00 | 4.59e-07 | 2.79e-06 | -1.57e-01 |
| ESCA | cg26997028 | chr5:76717002 | CGI:chr5:76715295-76716467 | promoter,gene body | 5.79e-01 | 6.82e-01 | -2.71e+00 | 6.75e-03 | 2.07e-02 | -1.03e-01 |
| THYM | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 4.07e-01 | 1.44e-01 | 6.65e+00 | 2.84e-11 | 1.35e-10 | 2.63e-01 |
| DLBC | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 6.91e-01 | 8.38e-01 | 2.88e+00 | 4.03e-03 | 1.15e-02 | -1.47e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg14773260 | chr5:76715498 | CGI:chr5:76715295-76716467 | promoter | 1.80e-01 | 7.01e-02 | 2.26e+00 | 2.36e-02 | 2.71e-02 | 1.10e-01 |
| LUAD | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 3.23e-01 | 1.97e-01 | 2.04e+00 | 4.14e-02 | 4.29e-02 | 1.25e-01 |
| LUSC | cg24678700 | chr5:76715313 | CGI:chr5:76715295-76716467 | promoter | 1.73e-01 | 2.18e-02 | 3.69e+00 | 2.22e-04 | 1.03e-03 | 1.51e-01 |
| LUSC | cg14718568 | chr5:76715479 | CGI:chr5:76715295-76716467 | promoter | 2.53e-01 | 2.28e-02 | 3.61e+00 | 3.09e-04 | 1.24e-03 | 2.30e-01 |
| LUSC | cg19735421 | chr5:76714773 | CGI:chr5:76715295-76716467 | promoter | 5.56e-01 | 4.55e-01 | 2.09e+00 | 3.65e-02 | 3.87e-02 | 1.00e-01 |
| LUSC | cg04528371 | chr5:76715302 | CGI:chr5:76715295-76716467 | promoter | 3.37e-01 | 1.05e-01 | 3.12e+00 | 1.79e-03 | 3.87e-03 | 2.32e-01 |
| LUSC | cg14773260 | chr5:76715498 | CGI:chr5:76715295-76716467 | promoter | 2.93e-01 | 4.92e-02 | 3.61e+00 | 3.09e-04 | 1.24e-03 | 2.44e-01 |
| LIHC | cg14773260 | chr5:76715498 | CGI:chr5:76715295-76716467 | promoter | 2.22e-01 | 6.78e-02 | 2.56e+00 | 1.04e-02 | 1.27e-02 | 1.55e-01 |
| LIHC | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 7.23e-01 | 2.14e-01 | 3.20e+00 | 1.37e-03 | 2.09e-03 | 5.09e-01 |
| KIRP | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 3.14e-01 | 1.74e-01 | 3.93e+00 | 8.37e-05 | 2.23e-04 | 1.40e-01 |
| ESCA | cg24678700 | chr5:76715313 | CGI:chr5:76715295-76716467 | promoter | 1.78e-01 | 2.61e-02 | 2.17e+00 | 2.97e-02 | 4.37e-02 | 1.52e-01 |
| ESCA | cg14718568 | chr5:76715479 | CGI:chr5:76715295-76716467 | promoter | 2.74e-01 | 2.88e-02 | 2.90e+00 | 3.75e-03 | 3.38e-02 | 2.46e-01 |
| ESCA | cg14773260 | chr5:76715498 | CGI:chr5:76715295-76716467 | promoter | 3.23e-01 | 6.19e-02 | 3.18e+00 | 1.49e-03 | 3.37e-02 | 2.61e-01 |
| ESCA | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 5.23e-01 | 3.56e-01 | 1.99e+00 | 4.71e-02 | 4.87e-02 | 1.67e-01 |
| CHOL | cg14773260 | chr5:76715498 | CGI:chr5:76715295-76716467 | promoter | 2.03e-01 | 7.48e-02 | 1.99e+00 | 4.65e-02 | 4.65e-02 | 1.29e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg11591325 | chr5:76716766 | CGI:chr5:76715295-76716467 | UTR,promoter,exon,gene body | 1.93e-01 | 2.94e-02 | 7.49e+00 | 6.91e-14 | 2.31e-13 | 1.63e-01 |
| BRCA | cg09059904 | chr5:76716932 | CGI:chr5:76715295-76716467 | promoter,gene body | 5.84e-01 | 2.40e-01 | 6.66e+00 | 2.75e-11 | 7.55e-11 | 3.43e-01 |
| HNSC | cg14714391 | chr5:76714619 | CGI:chr5:76715295-76716467 | promoter | 6.06e-01 | 7.97e-01 | -2.94e+00 | 3.27e-03 | 1.13e-02 | -1.91e-01 |
| HNSC | cg26594335 | chr5:76714647 | CGI:chr5:76715295-76716467 | promoter | 7.10e-01 | 8.44e-01 | -2.60e+00 | 9.28e-03 | 1.79e-02 | -1.34e-01 |
| HNSC | cg19735421 | chr5:76714773 | CGI:chr5:76715295-76716467 | promoter | 5.62e-01 | 7.11e-01 | -2.62e+00 | 8.69e-03 | 1.73e-02 | -1.49e-01 |
| HNSC | cg03043127 | chr5:76714833 | CGI:chr5:76715295-76716467 | promoter | 5.14e-01 | 6.74e-01 | -2.85e+00 | 4.37e-03 | 1.26e-02 | -1.61e-01 |
| BLCA | cg26594335 | chr5:76714647 | CGI:chr5:76715295-76716467 | promoter | 7.45e-01 | 5.71e-01 | 3.21e+00 | 1.34e-03 | 5.53e-03 | 1.74e-01 |
| BLCA | cg19735421 | chr5:76714773 | CGI:chr5:76715295-76716467 | promoter | 5.81e-01 | 4.50e-01 | 2.44e+00 | 1.47e-02 | 2.22e-02 | 1.31e-01 |
| BLCA | cg03043127 | chr5:76714833 | CGI:chr5:76715295-76716467 | promoter | 5.75e-01 | 4.25e-01 | 2.60e+00 | 9.25e-03 | 1.66e-02 | 1.50e-01 |
Top |
Exon skipping events with PSI in TCGA for F2R |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for F2R |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for F2R |
| TFs related to F2R. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | HIC1 | F2R | 4.21e+00 | 9.80e-01 | 3.32e+00 | 8.53e-03 | Male-biased |
| DLBC | PLAGL2 | F2R | 4.01e+00 | 9.83e-01 | 2.69e+00 | 1.64e-03 | Male-biased |
| DLBC | ZKSCAN2 | F2R | 3.61e+00 | 3.65e-03 | 4.79e+00 | 9.92e-01 | Female-biased |
| DLBC | ZNF33B | F2R | 3.59e+00 | 2.69e-03 | 4.86e+00 | 9.94e-01 | Female-biased |
| ESCA | DNMT1 | F2R | 4.00e+00 | 9.86e-01 | 2.97e+00 | 1.64e-03 | Male-biased |
| ESCA | MBD2 | F2R | 4.18e+00 | 9.88e-01 | 3.28e+00 | 3.47e-03 | Male-biased |
| ESCA | TCFL5 | F2R | 4.10e+00 | 9.84e-01 | 3.28e+00 | 5.40e-03 | Male-biased |
| ESCA | ZNF141 | F2R | 4.13e+00 | 9.83e-01 | 3.36e+00 | 7.45e-03 | Male-biased |
| ESCA | ZNF28 | F2R | 4.05e+00 | 9.84e-01 | 3.20e+00 | 4.85e-03 | Male-biased |
| ESCA | ZNF37A | F2R | 4.19e+00 | 9.86e-01 | 3.35e+00 | 4.86e-03 | Male-biased |
| ESCA | ZNF783 | F2R | 4.30e+00 | 9.87e-01 | 3.49e+00 | 5.87e-03 | Male-biased |
| ESCA | ZNF816 | F2R | 4.15e+00 | 9.83e-01 | 3.37e+00 | 6.90e-03 | Male-biased |
| GBM | DNMT1 | F2R | 4.28e+00 | 9.81e-01 | 3.13e+00 | 8.22e-03 | Male-biased |
| READ | HIC1 | F2R | 4.60e+00 | 9.81e-01 | 3.84e+00 | 1.26e-02 | Male-biased |
| READ | PLAGL2 | F2R | 4.62e+00 | 9.89e-01 | 3.61e+00 | 4.68e-03 | Male-biased |
| SARC | ZKSCAN2 | F2R | 3.87e+00 | 9.36e-03 | 4.52e+00 | 9.85e-01 | Female-biased |
| SARC | ZNF33B | F2R | 3.88e+00 | 9.18e-03 | 4.54e+00 | 9.85e-01 | Female-biased |
| SKCM | SPI1 | F2R | 3.54e+00 | 6.21e-03 | 4.67e+00 | 9.83e-01 | Female-biased |
| SKCM | ZKSCAN2 | F2R | 3.95e+00 | 1.23e-03 | 5.59e+00 | 9.96e-01 | Female-biased |
| SKCM | ZNF33B | F2R | 3.93e+00 | 1.08e-03 | 5.61e+00 | 9.96e-01 | Female-biased |
| F2R related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for F2R |
| RBPs related to ES in F2R. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| F2R related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000181104 | AC011447.3,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | OSMR-AS1,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | FAM66C,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | PCAT19,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | AC117453.1,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | AC019205.1,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | SP2-AS1,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | AL024507.2,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
| ENSG00000181104 | AC243960.1,hsa-mir-150,F2R | Female-specific ceRNA | TCGA-KICH |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs309556 | chr5:83544440:T:C | - | 0.140977354375539 | 0.0442905587024546 | LUSC | Female-baised eQTL |
| rs17302774 | chr5:72211646:T:C | - | 0.0959348093849196 | 0.0329119078888215 | LGG | Female-baised eQTL |
| rs7702802 | chr5:80363359:T:C | - | 0.222776396415375 | 0.0128912568121419 | BLCA | Female-baised eQTL |
| rs145224048 | chr5:76248657:C:T | - | 0.219996297049683 | 0.0473247948299475 | BLCA | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs3776925 | chr5:78017915:A:G | - | 0.291525588886218 | 0.00398860222563519 | PCPG | Male-baised eQTL |
| rs1566628 | chr5:81911278:G:C | - | 0.173942237471986 | 0.0445908117278015 | READ | Male-baised eQTL |
| rs10942426 | chr5:86075029:A:C | - | 0.0946687895215419 | 0.0336058211916735 | THCA | Male-baised eQTL |
| rs1108507 | chr5:78499980:T:A | - | 0.0598291945775691 | 0.0389248306897388 | LIHC | Male-baised eQTL |
| rs12186533 | chr5:78501415:T:G | - | 0.0598291945775691 | 0.0389248306897388 | LIHC | Male-baised eQTL |
| rs34007998 | chr5:81743998:C:T | - | 0.0668853997832103 | 0.0359261076028702 | LUAD | Male-baised eQTL |
| rs424762 | chr5:81728698:A:G | - | 0.065820186280493 | 0.0371769496494919 | LUAD | Male-baised eQTL |
| rs12186581 | chr5:81747437:T:C | - | 0.0668852369081619 | 0.0388766815524697 | LUAD | Male-baised eQTL |
| rs422523 | chr5:81738741:A:G | - | 0.0656671314183557 | 0.0423259547054861 | LUAD | Male-baised eQTL |
| rs402433 | chr5:81736143:A:C | - | 0.0649476937731919 | 0.0488907575702031 | LUAD | Male-baised eQTL |
| rs2202114 | chr5:76541652:T:C | - | -0.0717500668270275 | 0.00215221224294094 | COAD | Male-baised eQTL |
| rs77220634 | chr5:72999241:C:T | - | 0.13272515859123 | 0.0036767001838675 | COAD | Male-baised eQTL |
| rs75599919 | chr5:73011938:G:T | - | 0.113238059012164 | 0.0150388134354301 | COAD | Male-baised eQTL |
| rs16902534 | chr5:73012925:T:C | - | 0.113238059012164 | 0.0150388134354301 | COAD | Male-baised eQTL |
| rs58543164 | chr5:73014287:C:T | - | 0.113238059012164 | 0.0150388134354301 | COAD | Male-baised eQTL |
| rs74290475 | chr5:73026054:C:T | - | 0.113238059012164 | 0.0150388134354301 | COAD | Male-baised eQTL |
| rs182675972 | chr5:76813050:G:C | - | 0.0846541486455994 | 0.032941713256839 | COAD | Male-baised eQTL |
| rs10077409 | chr5:85149972:T:C | - | 0.101506043637691 | 0.0368495641356661 | COAD | Male-baised eQTL |
| rs4515323 | chr5:85150557:T:G | - | 0.100419315689761 | 0.0405262923171124 | COAD | Male-baised eQTL |
| rs78835566 | chr5:73018063:A:T | - | 0.108133119311492 | 0.0444044933255439 | COAD | Male-baised eQTL |
| rs75212227 | chr5:73035905:G:A | - | 0.108133119311492 | 0.0444044933255439 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000181104 |
| CpG Site: cg26594335 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.438058377550255 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg26594335 | chr5:76714647 | promoter | -0.438058377550255 | 1.08626219036388e-11 | -0.4602867118390391 | 2.0828945852414038e-14 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of F2R |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000181104 | F2R | C0015695 | Fatty Liver | 3 | CTD_human |
| ENSG00000181104 | F2R | C0019158 | Hepatitis | 1 | CTD_human |
| ENSG00000181104 | F2R | C0021368 | Inflammation | 1 | CTD_human |
| ENSG00000181104 | F2R | C0023890 | Liver Cirrhosis | 1 | CTD_human |
| ENSG00000181104 | F2R | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| ENSG00000181104 | F2R | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| ENSG00000181104 | F2R | C0027659 | Neoplasms, Experimental | 1 | CTD_human |
| ENSG00000181104 | F2R | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| ENSG00000181104 | F2R | C0239946 | Fibrosis, Liver | 1 | CTD_human |
| ENSG00000181104 | F2R | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| ENSG00000181104 | F2R | C2711227 | Steatohepatitis | 3 | CTD_human |
